79 results
8-K
EX-99.1
CNSP
Cns Pharmaceuticals Inc
16 May 24
Company committed to addressing the most aggressive type of brain cancer with an average survival of only 14 to 16 months after diagnosis and no cure
10:56am
in legal and professional fees and other expenses.
The Company reported research and development expenses of $2.4 million for the three months ended … March 31, 2024 compared to approximately $3.6 million for the comparable period in 2023. The decrease in research and development expenses during
8-K
EX-99.1
CNSP
Cns Pharmaceuticals Inc
1 Apr 24
Berubicin study enrollment completed; Topline data expected in first half of 2025
5:01pm
to increased research and development costs.
The Company reported research and development expenses of $14.1 million for the year ended December 31, 2023 … compared to approximately $9.3 million for the comparable period in 2022. The increase in research and development expenses during the period were mainly
8-K
EX-10.1
kc8xf1s8chr6eu
2 Feb 24
Entry into a Material Definitive Agreement
5:00pm
8-K
t2dz5rc39o7ajzde02t6
2 Feb 24
Entry into a Material Definitive Agreement
5:00pm
424B4
s0370k
31 Jan 24
Prospectus supplement with pricing info
4:27pm
424B3
xp3pd70q9drtubs guv5
30 Nov 23
Prospectus supplement
5:20pm
8-K
EX-99.1
jr7n1duv
15 Nov 23
Results of Operations and Financial Condition
8:00am